Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the effectiveness of St. John’s Wort as compared to placebo (an inactive substance) in the treatment of outpatients with social phobia.


Clinical Trial Description

Social Phobia is a prevalent and debilitating condition, with a lifetime prevalence rate to be 13.3 percent. Socially phobic patients have been found to be functionally impaired in the areas of education, employment and social relationships, to have poorer quality of life, and increased suicidal ideation and psychiatric comorbidity. Double-blind studies have found benzodiazepines, selective and non-selective MAOI inhibitors, several SSRIs, and the anticonvulsants pregabalin and gabapentin to be effective. However, side effects with these compounds suggests the need for better tolerated compounds, e.g., in the paroxetine multi-center trial (the only drug with an FDA approved indication), 27 percent reported somnolence, 26 percent nausea, and 37 percent of males reported delayed ejaculation; 34 percent of patients discontinued the trial early. There has been considerable worldwide interest in St. John's Wort (SJW) (Hypericum perforatum) as a treatment of mild to moderate depression. There have been 23 randomized trials suggesting SJW is more effective than placebo for the treatment of outpatients with mild to moderate depression. SJW is very well tolerated with mild side effects observed in only 2.5 percent of cases in a large (3250 patients) drug monitoring study. Pharmacokinetic studies have found Hypericum to have affinity for serotonin, dopamine and GABA alpha and GABA beta receptors, each of which have been implicated in social phobia, thus there is a suggestion that SJW may be effective for this disorder.

This will be a 12-week, double blind, placebo-controlled trial, designed to generate effect size data that will be used to determine sample size needed to power a definitive study. Forty patients will be randomized to either SJW (LI 160) or matching placebo. This will be a flexible-dose design, starting at 300 mg tid to a maximum of 1800 mg total per day. An intent-to-treat analysis will be employed. Subjects will be evaluated weekly for two weeks, then bi-weekly thereafter. The primary outcome measure will be the change from baseline to endpoint on the Liebowitz Social Anxiety Scale. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00035412
Study type Interventional
Source National Center for Complementary and Integrative Health (NCCIH)
Contact
Status Completed
Phase Phase 2
Start date December 2001
Completion date August 2004

See also
  Status Clinical Trial Phase
Completed NCT01963806 - ACT-smart: Smartphone-supplemented iCBT for Social Phobia and/or Panic Disorder N/A
Completed NCT00121069 - Study of Escitalopram in the Treatment of Specific Phobia Phase 2/Phase 3
Recruiting NCT03653923 - Neurophysiological Correlates of Exposition Therapy in Spider Phobia N/A
Completed NCT00184106 - RCT of Cognitive Therapy, Paroxetine, Combined CT and Paroxetine and Placebo Phase 4
Completed NCT00051220 - Treatment for Specific Phobias in Children Phase 1/Phase 2
Completed NCT02310152 - Explanatory Clinical Trial of a Novel Parent Intervention for Childhood Anxiety (SPACE) N/A
Completed NCT02387047 - Validity of a Self-administered Questionnaire to Screen Phobia of Falling in the Elderly N/A
Completed NCT00000370 - Treatment of Social Phobia N/A
Completed NCT03012035 - The Role of Treatment Expectation in Exposure Training With Spider Fearful Participants N/A
Completed NCT02007694 - Noradrenergic Manipulation and Virtual Reality Exposure Therapy in Phobic Participants Phase 2/Phase 3
Active, not recruiting NCT03188575 - Effectiveness & Cost-effectiveness of Internet-delivered Interventions for Depression and Anxiety Disorders in IAPT N/A
Completed NCT02432703 - A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder Phase 2
Terminated NCT01574014 - Glucocorticoid Treatment for Social Phobia Phase 2
Completed NCT00734422 - Facilitation of Fear Extinction With Yohimbine Hydrochloride in Phobic Participants Phase 2/Phase 3
Not yet recruiting NCT02336802 - Threat-Avoidance Learning in Anxiety Patients N/A
Completed NCT01361074 - In Vivo Versus Augmented Reality Exposure for Small Animal Phobia N/A
Completed NCT00104195 - A Research Study of How Teens With and Without an Anxiety Disorder Make Decisions Phase 1
Completed NCT00128401 - Use of an Antibiotic as an Enhancer for the Treatment of Social Phobia Phase 2
Recruiting NCT02020824 - Virtual Reality and Concept of Control in the Treatment of Acrophobia N/A
Terminated NCT01623583 - Effect of Including Synera® in Discussions on Dialysis Access Conversion in Patients With Needle Phobias Phase 4